Skip to content
All Podcasts – Lifestyle
Author:
Halia Therapeutics
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
June 15, 2026
Halia Therapeutics to Participate in Jefferies 2026 Global Healthcare Conference
May 28, 2026
Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board
May 19, 2026
Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
March 5, 2026